Compare IVR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | CMPS |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.6M | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | IVR | CMPS |
|---|---|---|
| Price | $8.07 | $9.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.25 | ★ $25.38 |
| AVG Volume (30 Days) | 2.0M | ★ 5.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $150.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $2.25 |
| 52 Week High | $9.50 | $10.21 |
| Indicator | IVR | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 68.21 |
| Support Level | $8.05 | $4.56 |
| Resistance Level | $8.07 | $10.21 |
| Average True Range (ATR) | 0.16 | 0.79 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 6.02 | 86.06 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.